Typical aspects of ovarian carcinoma;Aktuelle Aspekte des Ovarialkarzinoms

Geburtshilfe und Frauenheilkunde

Volumn 56, Issue 7, 1996, Pages 331-344

  Dietl, J ^a,b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CISPLATIN;

CANCER SCREENING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; HEREDITY; HUMAN; OVARY CARCINOMA; REVIEW; TRANSVAGINAL ECHOGRAPHY;

EID: 0029738773     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1023265     Document Type: Review

References (220)

1. Arbuck, S. G.: Paclitaxel: What schedule? What dose? J. Clin. Oncol. 12 (1994) 233.
2. Atlas, M., J. Menczer: Massive hyperstimulation and borderline carcinoma of the ovary. Acta Obstet. Gynecol. Scand. 61 (1982) 261.
3. Austoker, J.: Screening for ovarian, prostatic, and testicular cancers. Brit. Med. J. 309 (1994) 315.
4. Averette, H. E., A. Steren, H. N. Nguyen: Screening in gynecologic cancers. Cancer 72 (1993) 1043.
5. Averette, H. E., M. F. Janicek, H. R. Menck: The national cancer data base report on ovarian cancer. Cancer 76 (1995) 1096.
6. Balasch, J., P. Barri: Follicular stimulation and ovarian cancer? Hum. Reprod. 8 (1993) 990.
7. Bamford, P. M., S. J. Steele: Uterine and ovarian carcinoma in a patient receiving gonadotrophin therapy: case report. Brit. J. Obstet. Gynaecol. 89 (1982) 962.
8. Beckmann, M. W., D. Niederacher, H. G. Schnürch, H. G. Bender: Die erbB-Gen-Familie: Bedeutung für die Tumorentwicklung, Prognose und für neue Therapiemodalitäten. Geburtsh. u. Frauenheilk. 53 (1993) 742.
9. Bell, D. A., R. E. Scully: Early de novo ovarian carcinoma. Cancer 73 (1994) 1859.
10. Ben Hur, H., R. Degani, M. Lancet, Z. Katz, F. Nissim, D. Rosenman: Ovarian carcinoma masquerading as ovarian hyperstimulation syndrome. Acta Obstet. Gynecol. Scand. 65 (1986) 813.
11. Berchuk, A., A. Kamel, R. Whitaker et al.: Overexpression of HER-2/ neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50 (1990) 4087.
12. Berchuk, A., R. C. Bast: Growth factors, oncogenes, and tumor-suppressor genes. In Markman, M., W. J. Hoskins (eds.): Cancer of the Ovary. Raven Press. Ltd., New York (1993) 61-78.
13. Berchuk, A., M. F. Kohler, M. P. Boente, G. C. Rodriguez, R. S. Whitaker, R. C. Bast: Growth regulation and transformation of ovarian epithelium. Cancer 71 (1993) 545.
14. Berchuk, A., M. F. Kohler, M. P. Hopkins et al.: Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol. Oncol. 52 (1994a) 232.
15. Berchuk, A., M. F. Kohler, J. R. Marks, R. Wiseman, J. Boyd, R. C. Bast: The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Amer. J. Obstet. Gynecol. 170 (1994b) 246.
16. Berek, J. S.: Second-look versus second-nature. Gynecol. Oncol. 44 (1992) 1
17. Berek, J. S.: Ovarian cancer spread: is laparoscopy to blame? Lancet 346 (1995a) 200.
18. Berek, J. S.: Interval debulking of ovarian cancer - an interim measure. N. Engl. J. Med. 332 (1995b) 675.
19. Biesecker, B. B., M. Boehncke, K. Calzone et al.: Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 269 (1993) 1970.
20. Blanc, B., C. D'Ercole, E. Nicoloso, L. Boubli: Laparoscopic management of malignant ovarian cysts: a 78-case national survey. Part. 2: Follow up and final treatment. Eur. J. Obstet. Gynecol. Reprod. Biol. 61 (1995) 147.
21. Bloss, J. D., S.-Y. Liao, R. E. Buller et al.: Extraovarian peritoneal serous papillary carcinoma. A case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol. Oncol. 50 (1993) 347.
22. Blythe, J. G., T. P. Wahl: Debulking surgery: Does it increase the quality of survival? Gynecol. Oncol. 14 (1982) 396.
23. Boring, C. C., T. S. Squires, T. Tong: Cancer statistics, 1994. CA Cancer J. Clin. 44 (1994) 7.
24. Bratschi, H. U., B. Heiz: Die pelviskopische In-toto-Entfernung von Ovarialtumoren in einem Beutel durch die hintere Kolpotomie. Geburtsh. u. Frauenheilk. 55 (1995) 383.
25. Broun, E. R., J. L. Belinson, J. S. Berek: Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: a gynecologic oncology group pilot study. Gynecl. Oncol. 54 (1994) 142.
26. Buller, R. E., B. Anderson, J. P. Connor, M. Robinson: Familial ovarian cancer. Gynecol. Oncol. 51 (1993) 160.
27. Burghardt, E., M. Lahousen, H. Stettner: The significance of pelvic and paraaortic lymphadenectomy in the operative treatment of ovarian cancer. In Burghardt, E., J. M. Monaghan (eds.): Baillière's clinical obstetrics and gynecology. Operative Treatment of Ovarian Cancer. Baillière Tindall, London Vol. 3, 1989 (157-165).
28. Burghardt, E., F. Girardi, M. Lahousen, K. Tamussino, H. Stettner: Patterns of pelvic and paraaortic lymphnode involvement in ovarian cancer. Gynecol. Oncol. 40 (1991) 103.
29. Burke, Th. W., M. Morris: Secondary cytoreductive surgery for ovarian cancer. In Gershenson, D. M. (ed.): Obstetrics and Gynecology Clinics of North America. Update on Epithelial Ovarian Cancer. W. B. Saunders, Philadelphia, Vol. 21, 1994 (167).
30. Canis, M., A. Mage, J. Wattiez et al.: Tumor dissemination following laparoscopic excision of an ovarian cancer (stage Ia) case report. In Bruhat, M. A. (ed.): The Management of Adnexal Cysts. Blackwell Scientific Publications, Oxford, 1994 (109-113).
31. Cannistra, S. A.: Cancer of the ovary. N. Engl. J. Med. 329 (1993) 1550.
32. Cannistra, S. A., G. S. Kansas, J. Niloff, B. Defranzo, Y. Kim, C. Ottensmeier: Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44 H. Cancer Res. 53 (1993) 3830.
33. Cannistra, S. A., C. Ottensmeier, J. Niloff, B. Orta, J. DiCarlo: Expression and function of β1 and αvβ3 integrins in ovarian cancer. Gynecol. Oncol. 58 (1995) 216.
34. Carson, L. F., S. C. Rubin: Secondary cytoreduction - thoughts on the "pro" side. Gynecol. Oncol. 51 (1993) 127.
35. Carter, M. E., D. N. Joyce: Ovarian carcinoma in a patient hyperstimulated by gonadotrophin therapy for in vitro fertilization: a case report. J. In vitro Fert. Embryo Transfer 4 (1987) 126.
36. Carter, J., A. Saltzmann, E. Hartenbach, J. Fowler, L. Carson, L. B. Twiggs: Flow characteristic in benign and malignant gynecologic tumors using transvaginal color flow doppler. Obstet. Gynecol. 83 (1994) 125.
37. Chen, S. S., R. Bochner: Assessment of morbidity and mortality in primary cytoreduction surgery for advanced ovarian carcinoma. Gynecol. Oncol. 20 (1985) 190.
38. Chen, K. T., J. L. Schooley, M. S. Flam: Peritoneal carcinomatosis after propylactic oophorectomy in familial ovarian cancer syndrome. Obstet. Gynecol. 66 (1985) 93.
39. Childerrs, J. M., K. A. Aqua, E. A. Surwiz, A. V. Hallum, K. D. Hatch: Abdominal-wall tumor implantation after laparoscopy for malignant conditions. Obstet. Gynecol. 84 (1994) 765.
40. Childers, J. M., J. Lang, E. A. Surwit, K. D. Hatch: Laparoscopic surgical staging of ovarian cancer. Gynecol. Oncol. 59 (1995) 25.
41. Cohen, J., R. Forman, S. Harlap et al.: IFFS Expert Group Report on the Whittemore study related to the risk of ovarian cancer associated with the use of infertility agents. Hum. Reprod. 8 (1993) 996.
42. Cohen, C. J., T. S. Jennings: Screenng for ovarian cancer: the role of noninvasive imaging techniques. Amer. J. Obstet. ynecol. 170 (1994) 1088.
43. Cruickshank, D. J., N. Haites, S. Anderson et al.: The multidisciplinary management of a familiy with epithelial ovarian cancer. Brit. J. Obstet. Gynecol. 99 (1992) 226.
44. Culter, S. J., J. L. Young (eds.: Third National Survey: incidence data. U. S. Governmental Printing Office, Washington, D. C. 1975. Natl. Cancer Inst. Monogr., DHEW publication 41 (1975) 74.
45. Dalrymple, J. C., P. Bannatyne, H. J. Russel et al.: Extraovarian peritoneal serous papillary carcinoma: A clinicopathologic study of 31 cases. Cancer 94 (1989) 110.
46. Dembo, A. J., M. Davy, A. E. Stenwig, E. J. Berle, R. S. Bush, K. Kjorstad: Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet. Gynecol. 75 (1990) 263.
47. De Priest, P. D., D. Shenson, A. Fried et al.: A morphology index based on sonographic findings in ovarian cancer. Gynecol. Oncol. 51 (1993a) 7.
48. De Priest, P. D., J. R. van Nagell, H. H. Gallion et al.: Ovarian cancer screening in asymptomatic postmenopausal women. Gynecol. Oncol. 51 (1993b) 205.
49. De Priest, P. D., E. Varner, J. Powell et al.: The efficacy of a sonographic morphologic index in identifying ovarian cancer: a multi-institutional investigation. Gynecol. Oncol. 55 (1994) 174.
50. Dietl, J., F. Buchholz, P. Stoll: Das ovarielle Deckepithel und seine histogenetische Beziehung zum Ovarialkarzinom. Geburtsh. u. Frauenheilk. 46 (1986) 561.
51. Dietl, J.: Ovulation and ovarian cancer. Lancet 2 (1991) 445.
52. Dietl, J., H.-P. Horny, P. Ruck, E. Kaiserling: Dysgerminona of the ovary. An immunohistochemical study of tumor-infiltrating lymphoreticular cells and tumor cells. Cancer 71 (1993) 2562.
53. Dietl, J., K. Marzusch: Ovarian surface epithelium and human ovarian cancer. Gynecol. Obstet. Invest. 35 (1993) 129.
54. Dietl, J., H.-P. Horny, P. Ruck, U. Schumacher: Ultrastructural and immunohistochemical aspects of the surface epithelium and cystadenocarcinoma of the ovary. In Sharp, F., R. Leake, T. Blackett, J. Berek (eds.): Ovarian Cancer 4. Chapman and Hall, London (1996) im Druck.
55. Droegemüller, W.: Screening for ovarian carcinoma: Hopeful and wishful thinking. Amer. J. Obstet. Gynecol. 170 (1994) 1095.
56. Easton, D. F., D. T. Bishop, D. Ford et al.: Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. Amer. J. Hum. Genet. 52 (1993) 678.
57. Eccles, D. M., G. Cranston, C. M. Steel et al.: Allele losses on chromosome 17 in human epithelial ovarian carcinoma. Oncogene 5 (1990) 1599.
58. Einhorn, N., K. Sjövall, R. C. Knapp et al.: Prospective evaluation of serum CA125 levels for early detection of ovarian cancer. Obstet. Gynecol. 80 (1992) 14.
59. Einzig, A. J., P. H. Wiernick, J. Sasloff et al.: Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. Proc. ASCO 31 (1990) 187.
60. Eisenhauer, E. A., W. W. ten Bokkel Huinink, K. D. Swenerton et al.: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J. Clin. Oncol. 12 (1994) 2654.
61. Farias-Eisner, R., F. Teng, M. Oliveira et al.: The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol. Oncol. 55 (1995) 108.
62. Finn, C. B., D. M. Luesley, E. J. Buxton et al.: Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. Brit. J. Obstet. Gynecol. 99 (1992) 54.
63. Folkman, J., K. Watson, D. Ingber, D. Hanahan: Induction of angiogenesis during transition from hyperplasia to neoplasia. Nature 339 (1989) 58.
64. Foulkes, W. D., J. Trowsdale: Isolating tumour suppressor genes relevant to ovarian carcinoma: the role of loss of heterozygosity. In Sharp, F., P. Mason, T. Blacket, J. Berek (eds.): Ovarian Cancer 3. Chapman and Hall, London (1995) 23-38.
65. Franceschi, S., C. LaVecchia, E. Negri et al.: Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum. Reprod. 9 (1994) 1673.
66. Friedman, J. B., N. S. Weiss: Second thoughts about second-look laparotomy in advanced ovarian cancer. N. Engl. J. Med. 322 (1991) 1079.
67. Fromm, G. L., D. M. Gershenson, E. G. Silva: Papillary serous carcinoma of the peritoneum. Obstet. Gynecol. 75 (1990) 75.
68. Gershenson, D. M.: Primary cytoreduction for advanced epithelial ovarian cancer. In Gershenson, D. M. (ed.): Obstetrics and Gynecology Clinics of North America, Vol. 21, Update on Epithelial Ovarian Cancer. W. B. Saunders, Philadelphia (1994) 121-140.
69. Gleeson, N. C., S. V. Nicosia, J. E. Mark, M. S. Hoffmann, D. Cavanagh: Abdominal wall metastases from ovarian cancer after laparoscopy. Am. J. Obstet. Gynecol. 169 (1993) 522.
70. Goldberg, G. L., C. D. Runowicz: Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation - is there a link? Amer. J. Obstet. Gynecol. 166 (1992) 853.
71. Goldie, J. H., A. J. Goldman: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatm. Rep. 63 (1979) 1727.
72. Goodman, H. M., B. L. Harlow, E. E. Sheets et al.: The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. Gynecol. Oncol. 46 (1992) 367.
73. Griffith, C. T.: Surgical resection of tumor bulk in the primary treatment of ovarian cancer. Nat. Cancer Inst. Monogr. 42 (1975) 101.
74. Guidozzi, F., J. H. S. Ball: Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol. Oncol. 53 (1994) 326.
75. Hacker, N. F.: Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer - therapeutic advance or surgical folly? Gynecol. Oncol. 56 (1995) 325.
76. Hacker, N. F., J. S. Berek, L. D. Lagasse et al.: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet. Gynecol. 61 (1983) 413.
77. Hamilton, S. R.: Molecular genetics of colorectal carcinoma. Cancer 70 (1992) 1216.
78. Harlow, B. L., N. S. Weiss, G. J. Roth, J. Chen, J. R. Daling: Case-control study of borderline tumors: reproductive history and exposure to exogenous female hormones. Cancer Res. 48 (1988) 5849.
79. Harris, R., A. S. Whittemore, J. Intyre, and the Collaborative Ovarian Cancer Group: Characteristics relating to ovarian cancer risks: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Amer. J. Epidemiol. 136 (1992) 1204.
80. Hartge, P., M. H. Schiffman, R. Hoover, L. McGowan, L. Lesher, H. J. Norris: A case-control study of epithelial ovarian cancer. Amer. J. Obstet. Gynecol. 161 (1989) 10.
81. Hartmann, L. S., K. C. Podratz, G. L. Keeney: Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J. Clin. Oncol. 12 (1994) 64.
82. Herbst, A. L.: The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Amer. J. Obstet. Gynecol. 170 (1994) 1099.
83. Heintz, A. P. M., N. F. Hacker, J. S. Berek et al.: Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity. Obstet. Gynecol. 67 (1986) 783.
84. Hirsch, H. A., O. Käser, F. A. Iklé: Atlas der gynäkologischen Operationen. 5. Auflage. Thieme Verlag, Stuttgart (1995).
85. Hom-Ross, P. L., A. S. Whittemore, R. Harris, J. Intyre and Collaborative Ovarian Cancer Group: Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 U.S. case-control studies. IV. Nonepithelial cancer among adults. Epidemiology 3 (1992) 490.
86. Hoskins, W. J.: The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer. Baillière's Clin. Obstet. Gynaecol. 3 (1989) 59.
87. Hoskins, W. J., B. N. Bundy, J. T. Thigpen: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecological Oncology Group study. Gynecol. Oncol. 47 (1992) 159.
88. Hoskins, W. J.: Primary Cytoreduction. In Markman, M., W. J. Hoskins (eds.): Cancer of the Ovary. Raven Press, New York (1993) 163-173.
89. Hoskins, W. J., W. P. McGuire, M. F. Brady et al.: The effect of diameter of largest residual disease of survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Amer. J. Obstet. Gynecol. 170 (1994) 974.
90. Hoskins, P. J., K. D. Swenerton: Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J. Clin. Oncol. 12 (1994) 60.
91. Hsiu, J. G., F. T. Given, G. M. Kemp: Tumor implantation after diagnostic laparoscopic biopsy of serous ovarian tumors of low malignant potential. Obstet. Gynecol. 68 S (1986) 90.
92. Hulka, J. F., W. J. Parker, M. W. Surrey, J. M. Phillips: Management of ovarian masses. AAGL 1990 Survey. J. Reprod. Med. 37 (1992) 599.
93. Hunter, R. W., N. D. E. Alexander, W. P. Soutter: Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Amer. J. Obstet. Gynecol. 166 (1992) 504.
94. IFFS: Fertility drugs and ovarian cancer. Fertil. Steril. 60 (1993) 406.
95. Jänicke, F., M. Hölscher, W. Kuhn, G. Schattenmann, J. R. Siewert, H. Graeff: Die radikale Rezidivoperation des Ovarialkarzinoms. In Meerpohl, H.-G., A. Pfleiderer, G. Z. Profous (Hrsg.): Das Ovarialkarzinom. Springer-Verlag, Heidelberg (1993) 53-61.
96. Jindal, S. K., D. M. Snoey, D. K. Lobb, J. H. Dorrington: Transforming growth factor a localization and role in surface epithelium of normal human ovaries and in ovarian carcinoma cells. Gynecol. Oncol. 53 (1994) 17.
97. Joly, D. J., A. M. Lilienfeld, E. L. Diamond, I. D. I. Bross: An epidemiologic study of the relationship of reproductive experience to cancer of the ovary. Amer. J. Epidemiol. 99 (1974) 190.
98. Kaldor, J. M., N. E. Day, F. Pettersen et al.: Leukemia following chemotherapy for ovarian cancer. N. Engl. J. Med. 322 (1990) 1.
99. Kalkarni, R., J. M. McGarry: Follicular stimulation and ovarian cancer. Brit. Med. J. 299 (1989) 740.
100. Karlan, B. Y., R. Marrs, L. D. Lagasse: Advanced - stage ovarian carcinoma presenting during infertility evaluation. Am. J. Obstet. Gynecol. 171 (1994) 1377.
101. Kiechle-Schwarz, M., Th., Bauknecht, U. Karck, F. Kommoss, A. Du Bois, A. Pfleiderer: Recurrent cytogenetic aberrations and loss of constitutional heterozygosity in ovarian carcinomas. Gynecol. Oncol. 55 (1994) 198.
102. Kindermann, G., V. Maaßen, W. Kuhn: Laparoskopisches "Anoperieren" von ovariellen Malignomen. Erfahrungen aus 127 deutschen Frauenkliniken. Geburtsh. u. Frauenheilk. 55 (1995) 687.
103. Kolbenstvedt, A., P. Kolstad: The difficulties of complete pelvic lymph node dissection in radical hysterectomy for carcinoma of the cervix. Gynecol. Oncol. 4 (1976) 244.
104. Komatsu, T., J. Konishi, M. Mandai et al.: Peritoneal papillary serous carcinoma arising in an infertile woman during ovulation - induction therapy: Immunohistochemical expression of LH/hCH receptors. Gynecol. Oncol. 56 (1995) 470.
105. Kühn, Th., S. Hock, H.-H. Zippel: Endoskopische Therapie von Adnextumoren unter Verwendung der Endobag-Extraktion. Geburtsh. u. Frauenheilk. 55 (1995) 684.
106. Lais, C. W., T. J. Williams, T. A. Gaftey: Prevalence of ovarian cancer found at the time of infertility microsurgery. Fertil. Steril. 49 (1988) 441.
107. Lauchlan, S. C.: The secondary müllerian system revisited. Int. J. Gynecol. Pathol. 13 (1994) 73.
108. Lerman, C., M. Daly, A. Masny, A. Balshem: Attitudes about genetic testing for breast-ovarian cancer susceptibility. J. Clin. Oncol. 12 (1994) 843.
109. Levin, L.: Dose intensity in the treatment of ovarian carcinoma. In Markman, M., W. J. Hoskins (eds.): Cancer of the Ovary. Raven Press, New York (1993) 251.
110. Li, T. C., H. Saravelos: Oophorectomy at the same time as hysterectomy. Brit. J. Obstet. Gynaecol. 101 (1994) 934.
111. Lopes, P., V. Julon, A. Mensier et al.: Cancer de l'ovaire et procreation medicalement assistee. Contracept. Fertil. Sexual. 20 (1992) 797-798.
112. Lotz, J. P., D. Machover, A. Bellaiche et al.: Tandem high-dose chemotherapy with VM-26, ifosfamide and carboplatin with autologous bone marrow transplantation for patients with stage IIIc-IV ovarian cancer. Proc. ASCO 12 (1993) 257.
113. Luxman, D., A. Bergman, J. Sagi, M. David: The postmenopausal adnexal mass: correlation between ultrasonic and pathologic findings. Obstet. Gynecol. 77 (1991) 726.
114. Lynch, H. T., R. E. Harris, H. J. Guirgis, K. Maloney, L. L. Carmody, J. F. Lynch: Familial association of breast/ovarian carcinoma. Cancer 41 (1978) 1543.
115. Lynch, H. T., W. Kimberlin, W. Albano et al.: Hereditary nonpolyposis colorectal cancer: part. I. Clinical description of resource. Cancer 56 (1985) 934.
116. Lynch, H. T., C. Bewtra, J. F. Lynch: Familial peritoneal ovarian carcinomatosis: A new clinical entitiy? Med. Hypothesis 21 (1986) 171.
117. Lynch, H. T.: Genetic risk in ovarian cancer. Gynecol. Oncol. 46 (1992) 1.
118. Lynch, H. T., J. F. Lynch: Hereditary ovarian carcinoma. Hematol. Oncol. Clin. North. Am. 6 (1992) 783.
119. Lynch, H. T., P. Watson, T. A. Conway et al.: DNA-screening for breast/ovarian cancer susceptibility based on linked markers: A family study. Arch. Intern. Med. 153 (1993) 1979.
120. Maaßen, V., G. Debus-Thiede: Das serös-papilläre Karzinom des Peritoneums: Eine multizentrische Primärerkrankung. Zentralbl. Gynäkol. 115 (1993) 347.
121. Maiman, M., V. Seltzer, J. Boyce: Laparoscopic excision of ovarian neoplasms subsequently found to be malignant. Obstet. Gynecol. 77 (1991) 563.
122. Makar, A. Ph., M. Baekelandt, C. G. Tropé, G. B. Kristensen: The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol. Oncol. 56 (1995) 175.
123. Markman, M., T. Hakes, B. Reimann et al.: Ifosfamide and Mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease. J. Clin. Oncol. 10 (1992) 243.
124. Marks, J. R., A. M. Davidoff, B. J. Kerns et al.: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 51 (1991) 2979.
125. McDonough, P. G.: Editorial comment. Fertil. Steril. 60 (1993) 200.
126. McGuire, W. P., W. J. Hoskins, M. F. Brady et al.: A phase III trial comparing cisplatin/cytoxan and cisplatin/taxol in advanced ovarian cancer. Proc. ASCO 12 (1993) 255.
127. McGuire, W. P., W. J. Hoskins, M. F. Brady et al.: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 13 (1995) 1589.
128. McGuire, W. P., J. W. Hoskins, M. F. Brady et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1.
129. Meden, H., W. Rath, W. Kuhn: Taxol - ein neues Zytostatikum zur Therapie des Ovarial- und Mammakarzinoms. Geburtsh. u. Frauenheilk. 54 (1994) 187.
130. Meden, H., D. Marx, W. Rath et al.: Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int. J. Gynecol. Pathol. 13 (1994) 45.
131. Medl, H., P. Sevelda, K. Czerwenka et al.: DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer. Gynecol. Oncol. 59 (1995) 321.
132. Meier, W., M. Romisch, H. Hepp: Stellenwert der tumorreduktiven Sekundäroperation (Interventionslaparotomie) beim Ovarialkarzinom. Geburtsh. u. Frauenheilk. 53 (1993) 860.
133. Michel, G., D. Zarca, D. Castainge, M. Prade: Secondary cytoreductive surgery in ovarian cancer. Eur. J. Surg. Oncol. 15 (1989) 201.
134. Michel, G., F. Rochard, M. Prade, B. Deval, D. Castaigne, P. Duvillard: Incidence and prognosis of intraoperative rupture of borderline ovarian tumors. In Bruhat, M. A. (ed.): The Management of Adnexal Cysts. Blackwell Scientific Publication, Oxford (1994) 116-121.
135. Miller, C., T. Mohandas, D. Wolf et al.: Human p53 gene localized to short arm of chromosome 17. Nature 319 (1986) 783.
136. Morris, M., D. M. Gershenson, J. T. Wharton: Secondary cytoreductive surgery in epithelial ovarian cancer: Nonresponders to first-line therapy. Gynecol. Oncol. 33 (1988) 1.
137. Morris, M., D. M . Gershenson, J. T. Wharton, L. J. Copeland, C. L. Edwards, C. A. Stringer: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol. Oncol. 34 (1989) 334.
138. Mulhollan, T. J., E. G. Silvo, C. Tornos, C. Guerrieri, G.-L. Fromm, D. M. Gershenson: Ovarian involvement by serous surface papillary carcinoma. Int. J. Gynecol. Pathol. 13 (1994) 120.
139. Narod, S. A., J. Fennteun, H. T. Lynch et al.: Familial breast-ovarian cancer iocus on chromosome 17q12 -q23. Lancet 338 (1991) 82.
140. Narod, S. A., L. Madlensky, L. Bradley et al.: Hereditary and familial ovarian cancer in southern Ontario. Cancer 74 (1994) 2341.
141. Neijt, J. P., E. J. Aartsen, J. Bouma, A. P. Heintz, M. van Leut, A. van Lindert. Cytoreductive surgery with or without preceding chemotherapy in ovarian cancer. Prog. Clin. Biol. Res. 201 (1985) 217.
142. Nguyen, H. N., H. E. Averette, M. Janicek: Ovarian Carcinoma. A review of the significance of familial risk factors and the role of prophylactic oophorectomy in cancer prevention. Cancer 74 (1994) 545.
143. Nicolaou, K. C., Z. Yang, J. J. Liu et al.: Total synthesis of taxol. Nature 367 (1994) 630.
144. Nijman, H. W., C. W. Burger, J. P. A. Baak, R. Schats, J. B. Vermorken, P. Kenemans: Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases. Eur. J. Cancer 28 A (1992) 1971.
145. Oram, D. H., A. R. Jeyarajah: The role of ultrasound and tumor markers in the early detection of ovarian cancer. Br. J. Obstet. Gynecol. 101 (1994) 939.
146. Ovarian Cancer: Screening, treatment, and follow up. JAMA 273 (1995) 491.
147. Parazzini, F., E. Negri, C. La Vecchia et al : Family history of reproductive cancers and ovarian cancer risk: an Italian case-control study. Am. J. Epidemiol. 135 (1992) 35.
148. Pazdur, R., A. P. Kudelka, J. J. Kavanagh, P. R. Cohen, M. N. Raber: The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer. Treat. Rev. 19 (1993) 351-386.
149. Pedersen-Bjergaard, J.: Long-term complications of cancer chemotherapy. J. Clin. Oncol. 13 (1995) 1534.
150. Perez, R. P., A. K. Godwin, T. C. Hamilton, R. F. Ozols: Ovarian cancer biology. Semin. Oncol. 18 (1991) 186.
151. Petru, E., M. Lahousen, K. Tamussino et al.: Lymphadenectomy in stage 1 ovarian cancer. Am. J. Obstet. Gynecol. 170 (1994) 656.
152. Petterson, F.: Annual report on the results of treatment in gynecological cancer. Int. J. Gynecol. Obstet. 36 (1991) Suppl. 1.
153. Pfleiderer, A.: Möglichkeiten des Tumor-Screenings in der Gynäkologie. Der Frauenarzt 36 (1995) 893.
154. Piver, M. S., T. Baker: The potential for optimal (≤ 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: A prospective study. Gynecol. Oncol. 24 (1986) 1.
155. Piver, M. S., S. B. Lele, D. L. Marchetti et al.: The impact of aggressive debulking surgery and cisplatin chemotherapy on progression-free survival in stage III and IV ovarian carcinomas. J. Clin. Obstet. Gynecol. 6 (1988) 983.
156. Piver, M. S., T. R. Baker, M. Piedmonte, A. M. Sandecki: Epidemiology and etiology of ovarian cancer. Semin. Oncol. 18 (1991) 177.
157. Piver, M. S., M. F. Jishi, Y. Tsukada, G. Nava: Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: a report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71 (1993) 2751.
158. Pomel, Ch., D. Provencher, J. Dauplat et al.: Laparoscopic staging of early ovarian cancer. Gynecol. Oncol. 58 (1995) 301.
159. Potter, M. E., E. E. Patridge, K. D. Hatach, S. Soong, J. R. Austin, H. M. Shingleton: Primary surgical therapy of ovarian cancer: how much and when? Gynecol. Oncol. 40 (1991) 195.
160. Potter, M. E., K. D. Hatch, S. J. Soong, E. E. Partridge, J. M. Austin, H. M. Shingleton: Second-look laparotomy and salvage therapy: A research mordality only? Gynecol. Oncol. 44 (1992) 3.
161. Potter, M. E.: Secondary cytoreduction in ovarian cancer: pro or con? Gynecol. Oncol. 51 (1993) 131.
162. Puls, L. E., D. E. Powell, P. D. De Priest et al.: Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol. Oncol. 47 (1992) 53.
163. Redman, J. R., G. R. Petroni, P. E. Saigo, N. L. Geller, T. B. Hakes: Prognostic factors in advanced ovarian cancer. J. Clin. Oncol. 4 (1986) 515.
164. Redman, C. W. E., J. Warwick, D. M. Luesley, R. Varma, F. G. Lawton, G. R. P. Blackledge: Intervention debulking surgery in advanced epithelial ovarian cancer. Br. J. Obstet. Gynaecol. 101 (1994) 142.
165. Resta, L., S. Russo , G. A. Cloucci, J. Prat: Morphologic precursors of ovarian epithelial tumors. Obstet. Gynecol. 82 (1993) 181.
166. Riggs, J. E.: Rising ovarian cancer mortality in the elderly: a manifestation of differential survival. Gynecol. Oncol. 58 (1995) 64.
167. Risinger, J. I., A. Berchuk, M. F. Kohler, J. Boyd: Mutations of E-cadherin gene in human gynecologic cancers. Nature Genetics 7 (1994) 98.
168. Rossing, M. A., J. R. Doling, N. S. Weiss, D. E. Moore, S. G. Self: Ovarian tumors in a cohort of infertile women. N. Engl. J. Med. 331 (1994) 771.
169. Rowinsky, E. K., R. C. Donehower: Paclitaxel (Taxol). N. Engl. J. Med. 332 (1995) 1004.
170. Rubin, S. C., C. L. Finstad, M. G. Federici, L. Scheiner, K. O. Lloyd, W. J. Hoskins: Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 73 (1994) 1456.
171. Sainz de la Cuesta, R., B. A. Goff, A. F. Fuller, N. Nikrui, J. H. Eichhorn, L. W. Rice: Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet. Gynecol. 84 (1994) 1.
172. Scarabelli, C., A. Gallo, A. Zarrelli, C. Visentin, E. Campagnutta: Systemic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival. Gynecol. Oncol. 56 (1995) 328.
173. Schildkraut, J. M., W. D. Thompson: Familial ovarian cancer: a population-based case-control study. Am. J. Epidemiol. 128 (1988) 456.
174. Seewaldt, V. L., B. E. Greer, J. M. Cain et al.: Paclitaxel (Taxol) treatment for refractory ovarian cancer: Phase II clinical trial. Am. J. Obstet. Gynecol. 170 (1994) 1666.
175. Segna, R. A., P. R. Dottino, J. P. Mandeli, K. Konsker, C. J. Cohen: Secondary cytoreduction for ovarian cancer following cisplatin therapy. J. Clin. Oncol. 11 (1993) 434.
176. Seidman, J. D., D. M. Frisman, H. J. Norris: Expression of the HER-2/ neu proto-oncogene in serous ovarian neoplasms. Cancer 70 (1992) 2857-2860.
177. Sevelda, P., C. Dittrich, H. Salzer: Prognostic value of the rupture of the capsule in stage I epithelial ovarian carcinoma. Gynecol. Oncol. 35 (1989) 321.
178. Shoham, Z.: Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: Where are we today? Fertil. Steril. 62 (1994) 433.
179. Shpall, E. J., D. Clarke-Pearson, J. T. Siper et al.: High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol. Oncol. 38 (1990) 386.
180. Shpall, E. J., S. M. Stemmer, S. J. Bearmann et al.: High-dose chemotherapy with autologous bone marrow support for the treatment of epithelial ovarian cancer. In Markman, M., W. J. Hoskins (eds.): Cancer of the Ovary. Raven Press, New York (1993) 327-338.
181. Shpall, E. J., R. B. Jones, S. I. Bearman, M. P. Purdy: Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support. Gynecol. Oncol. 54 (1994) 357.
182. Sightler, S., G. Boike, R. E. Estape, H. E. Averette: Ovarian cancer in women with prior hysterectomy: a 14-year experience at the University of Miami. Obstet. Gynecol. 78 (1991) 681.
183. Singleton, T. P., Th. Perrone, G. Oakley et al.: Activation of c-erbB-2 and prognosis in ovarian carcinoma. Cancer 73 (1994) 1460.
184. Sjövall, K., B. Nilsson, N. Einhorn: Incidence of and prognosis following intraoperative rupture of malignant ovarian tumors with immediate surgical treatment. In Bruhat, M. A. (ed.): The Management of Adnexal Cysts. Blackwell Scientific Publication, Oxford (1994a) 107-108.
185. Sjövall, K., B. Nilsson, N. Einhorn: Different types of rupture of the tumor capsule and the impact on survival in early ovarian carcinoma. Int. J. Gynecol. Cancer 4 (1994b) 333.
186. Slamon, D. J., W. Godolphin, L. A. Jones et al.: Studies of HER-2/neu protooncogene in human breast and ovarian cancer. Science 244 (1989) 707.
187. Spirtas, R., S. C. Kaufman, N. J. Alexander: Fertility drugs and ovarian cancer: red alert or red herring? Fertil. Steril. 59 (1993) 291.
188. Spirtos, N. M., G. M. Gross, J. L. Freddo, S. C. Ballon: Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy. Gynecol. Oncol. 56 (1995) 345.
189. Spurr, N. K., E. Solomon, M. Jansson et al.: Chromosomal localisation of the human homologues to the oncogenes erb A and B. EMBO 3 (1984) 159.
190. Stanford News Bureau: Ovarian cancer risks assessed in comprehensive study. News Bureau 1/12/93, Stanford University Medical Center, Stanford, California.
191. Steel, C. M., D. M. Eccles, L. Gruber et al.: Allele losses on chromosome 17 in ovarian tumours. In Sharp, F., P. Mason, T. Blackett, J. Berek (eds.): Ovarian Cancer 3. Chapman and Hall, London, pp. (1995) 45-52.
192. Steinkampf, M. P., R. Hammond, R. D. Alvarez, R. E. Blackwell: Assisted reproduction after treatment for ovarian malignancy. Fertil. Steril. 64 (1995) 22.
193. Stiff, P., R. Bayer, M. Camarda et al.: A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone bone marrow rescue for recurrent epithelial ovarian carcinoma: Analysis of risk factors for clinical outcome. Gynecol. Oncol. 57 (1995) 278.
194. Swenerton, K. D., E. Eisenhauer, W. Gen Bokkel Huinink et al.: Taxol in relapsed ovarian cancer: High vs low dose and short vs long infusion: A European-Canadian study coordinated by the NCI Canada Clinical Trials Group. Proc. ASCO 12 (1993) 256.
195. Teufel, G., M. Nicolai, U. Aisslinger, H. Simonis, H. G. Meerpohl, A. Pfleiderer: Operative Therapie progredienter oder rezidivieren-der maligner Ovarialtumoren. Geburtsh. u. Frauenheilk. 51 (1991) 186.
196. Thigpen, J. T., J. A. Blessing, H. Ball et al.: Phase II trial of taxol as second-line therapy for ovarian carcinoma: A Gynecologic Oncology Group study. Proc. ASCO 9 (1990) 156.
197. Thigpen, J. T., K. Bertelsen, E. A. Eisenhauer, N. F. Hacker, B. Lund, C. Sessa: Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy. Ann. Oncol. 4, Suppl. 4 (1993) 35.
198. Thigpen, J. T., J. A. Blessing, H. Ball, S. J. Hummel, R. J. Barrett: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J. Clin. Oncol. 12 (1994) 1748.
199. Thigpen, J. T.: High-dose chemotherapy with autologous bone marrow support in ovarian carcinoma: the bottom line, more or less. Gynecol. Oncol. 57 (1995) 275.
200. Tobacman, J. K., M. A. Tucker, R. Kase: Intraabdominal carcinomatosis after prophylactic oophorectomy in ovarian cancer prone families. Lancet 2 (1982) 795.
201. Toribara, N. W., M. H. Sleisenger: Screening for colorectal cancer. N. Engl. J. Med. 332 (1995) 861.
202. Tulandi, T., M. Bugnah: Operative laparoscopy: surgical modalities. Fertil. Steril. 63 (1995) 237.
203. Van der Burg, M. E. L., M. van Lent, M. Buyse et al.: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N. Engl. J. Med. 332 (1995) 629.
204. Van Eijkeren, M. A., J. de Graaff, F. H. van Etten: Familial ovarian cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 47 (1992) 263.
205. Van Nagell, J. R., P. D. De Priest, L. E. Puls et al.: Ovarian cancer screening in asymptomatic postmenopausal women by transvaginal sonography. Cancer 68 (1991) 458.
206. Van Nagell, J. R., P. D. De Priest: Early diagnosis of epithelial ovarian cancer. In Markman, W., W. J. Hoskins (eds.): Cancer of the Ovary. Raven Press, Ltd., New York (1993) 127-131.
207. Venesmaa, P.: Epithelial ovarian cancer: Impact of surgery and chemotherapy on survival during 1977-1990. Obstet. Gynecol. 84 (1994) 8.
208. Viens, P., D. Maraninchi, M. Legros et al.: High-dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: A retrospective analysis of 35 patients treated in France. Bone Marrow Transplant. 5 (1990) 227.
209. Walters, D. E.: Ovarian cancer and pregnancy: comment on a paper by Whittemore et al. Fertil. Steril. 61 (1994) 239.
210. Weiner, Z., J. Thaler, D. Beck et al.: Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol. 79 (1992) 159.
211. Whittemore, A. S., M. L. Wu, R. S. Paffenberger et al.: Epithelial ovarian cancer and the ability to conceive. Cancer Res. 49 (1989) 4047.
212. Whittemore, A. S., R. Harris, R. Intyre and Collaborative Ovarian Cancer Group: Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am. J. Epidemiol. 136 (1992) 1184.
213. Whittemore, A. S.: Fertility drugs and risk of ovarian cancer. Hum. Reprod. 8 (1993) 1999.
214. Whittemore, A. S.: The risk of ovarian cancer after treatment for infertility. N. Engl. J. Med. 331 (1994) 805.
215. Willemsen, W., R. Kruitwagen, B. Bastianns, T. Hanselaar, R. Rolland: Ovarian stimulation and granulosa-cell tumour. Lancet 341 (1993) 986.
216. Williams, L. L.: Secondary cytoreduction of the ovarian malignancies. In Markman, M., W. J. Hoskins (eds.): Cancer of Ovary. Raven Press, New York (1993) 187-203.
217. Young, R. C., L. A. Walton, S. S. Ellenburg et al.: Adjuvant therapy in stage I and stage II epithelial ovarian cancer. N. Engl. J. Med. 322 (1990) 1021.
218. Zeimet, A. G., F. Guadagni, C. Marth et al.: Stellenwert des Tumormarkers TAG-72 (CA 72-4) bei der Primärdiagnosrik des Ovanalkarzinoms. Geburtsh. u. Frauenheilk. 55 (1995) 195.
219. Zhou, J., Y. Iwasa, I. Konishi et al.: Papillary serous carcinoma of the peritoneum in women. Cancer 76 (1995) 429.
220. Zweizig, S., J. Zheng, M. Wan et al.: New insights into the genetics of human ovarian epithelial tumor development. In Sharp, F., P. Mason, T. Blackett, J. Berek (eds.): Ovarian Cancer 3. Chapman and Hall, London (1995) 61-73.